Is TTRX or VTVT more profitable?

vTv Therapeutics' return on equity of -6.27% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A -230.84% -53.19% vTv Therapeutics N/A -6.27% -5.06%

Does the media refer more to TTRX or VTVT?

In the previous week, Turn Therapeutics had 1 more articles in the media than vTv Therapeutics. MarketBeat recorded 3 mentions for Turn Therapeutics and 2 mentions for vTv Therapeutics. Turn Therapeutics' average media sentiment score of 0.41 beat vTv Therapeutics' score of 0.00 indicating that Turn Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral vTv Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is RLMD or VTVT more profitable?

vTv Therapeutics' return on equity of -6.27% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -47.52% -43.97% vTv Therapeutics N/A -6.27% -5.06%

Does the media prefer RLMD or VTVT?

In the previous week, vTv Therapeutics had 1 more articles in the media than Relmada Therapeutics. MarketBeat recorded 2 mentions for vTv Therapeutics and 1 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.79 beat vTv Therapeutics' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive vTv Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AVIR or VTVT more profitable?

vTv Therapeutics' return on equity of -6.27% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -64.25% -57.12% vTv Therapeutics N/A -6.27% -5.06%

Does the media refer more to VTVT or SPRY?

In the previous week, ARS Pharmaceuticals had 19 more articles in the media than vTv Therapeutics. MarketBeat recorded 21 mentions for ARS Pharmaceuticals and 2 mentions for vTv Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.11 beat vTv Therapeutics' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment vTv Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend VTVT or CGC?

vTv Therapeutics currently has a consensus price target of $55.83, indicating a potential upside of 78.84%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe vTv Therapeutics is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Does the media favor VTVT or CGC?

In the previous week, Canopy Growth had 19 more articles in the media than vTv Therapeutics. MarketBeat recorded 21 mentions for Canopy Growth and 2 mentions for vTv Therapeutics. Canopy Growth's average media sentiment score of 0.93 beat vTv Therapeutics' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment vTv Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Canopy Growth 14 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

vTv Therapeutics (VTVT) Competitors

$30.57 -1.28 (-4.02%)

Closing price 04:00 PM Eastern

Extended Trading

$31.54 +0.97 (+3.17%)

As of 07:30 PM Eastern

Compare

VTVT vs. TTRX, RLMD, AVIR, SPRY, and CGC

Should you buy vTv Therapeutics stock or one of its competitors? vTv Therapeutics's main competitors and comparable companies include Turn Therapeutics (TTRX), Relmada Therapeutics (RLMD), Atea Pharmaceuticals (AVIR), ARS Pharmaceuticals (SPRY), and Canopy Growth (CGC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does vTv Therapeutics compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Turn Therapeutics has higher earnings, but lower revenue than vTv Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than vTv Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
vTv Therapeutics	$1.02M	120.59	-$26.97M	-$1.06	N/A

17.5% of vTv Therapeutics shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Turn Therapeutics presently has a consensus target price of $9.00, indicating a potential downside of 26.80%. vTv Therapeutics has a consensus target price of $55.83, indicating a potential upside of 78.84%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe vTv Therapeutics is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.50
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

vTv Therapeutics' return on equity of -6.27% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
vTv Therapeutics	N/A	-6.27%	-5.06%

In the previous week, Turn Therapeutics had 1 more articles in the media than vTv Therapeutics. MarketBeat recorded 3 mentions for Turn Therapeutics and 2 mentions for vTv Therapeutics. Turn Therapeutics' average media sentiment score of 0.41 beat vTv Therapeutics' score of 0.00 indicating that Turn Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
vTv Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

vTv Therapeutics beats Turn Therapeutics on 9 of the 14 factors compared between the two stocks.

How does vTv Therapeutics compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Relmada Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 231.03%. vTv Therapeutics has a consensus target price of $55.83, suggesting a potential upside of 78.84%. Given Relmada Therapeutics' higher probable upside, analysts clearly believe Relmada Therapeutics is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, vTv Therapeutics had 1 more articles in the media than Relmada Therapeutics. MarketBeat recorded 2 mentions for vTv Therapeutics and 1 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.79 beat vTv Therapeutics' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
vTv Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

vTv Therapeutics has higher revenue and earnings than Relmada Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
vTv Therapeutics	$1.02M	120.59	-$26.97M	-$1.06	N/A

vTv Therapeutics' return on equity of -6.27% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-47.52%	-43.97%
vTv Therapeutics	N/A	-6.27%	-5.06%

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Relmada Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

Summary

Relmada Therapeutics and vTv Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does vTv Therapeutics compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

Atea Pharmaceuticals presently has a consensus price target of $7.00, indicating a potential upside of 37.66%. vTv Therapeutics has a consensus price target of $55.83, indicating a potential upside of 78.84%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe vTv Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, vTv Therapeutics had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 2 mentions for vTv Therapeutics and 0 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.00 equaled vTv Therapeutics'average media sentiment score.

Company	Overall Sentiment
Atea Pharmaceuticals	Neutral
vTv Therapeutics	Neutral

vTv Therapeutics' return on equity of -6.27% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
vTv Therapeutics	N/A	-6.27%	-5.06%

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

vTv Therapeutics has higher revenue and earnings than Atea Pharmaceuticals. vTv Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
vTv Therapeutics	$1.02M	120.59	-$26.97M	-$1.06	N/A

Atea Pharmaceuticals has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

Summary

vTv Therapeutics beats Atea Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does vTv Therapeutics compare to ARS Pharmaceuticals?

vTv Therapeutics (NASDAQ:VTVT) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

vTv Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

vTv Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. vTv Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	120.59	-$26.97M	-$1.06	N/A
ARS Pharmaceuticals	$84.28M	4.95	-$171.30M	-$2.18	N/A

In the previous week, ARS Pharmaceuticals had 19 more articles in the media than vTv Therapeutics. MarketBeat recorded 21 mentions for ARS Pharmaceuticals and 2 mentions for vTv Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.11 beat vTv Therapeutics' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	19 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

vTv Therapeutics presently has a consensus price target of $55.83, indicating a potential upside of 78.84%. ARS Pharmaceuticals has a consensus price target of $25.00, indicating a potential upside of 495.95%. Given ARS Pharmaceuticals' higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

vTv Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -184.24%. vTv Therapeutics' return on equity of -6.27% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

Summary

vTv Therapeutics beats ARS Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does vTv Therapeutics compare to Canopy Growth?

vTv Therapeutics (NASDAQ:VTVT) and Canopy Growth (NASDAQ:CGC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by company insiders. Comparatively, 0.4% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

vTv Therapeutics currently has a consensus price target of $55.83, indicating a potential upside of 78.84%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe vTv Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

vTv Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. vTv Therapeutics' return on equity of -6.27% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
Canopy Growth	-65.33%	-21.91%	-14.34%

In the previous week, Canopy Growth had 19 more articles in the media than vTv Therapeutics. MarketBeat recorded 21 mentions for Canopy Growth and 2 mentions for vTv Therapeutics. Canopy Growth's average media sentiment score of 0.93 beat vTv Therapeutics' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Canopy Growth	14 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

vTv Therapeutics has higher earnings, but lower revenue than Canopy Growth. vTv Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	120.59	-$26.97M	-$1.06	N/A
Canopy Growth	$251.01M	1.56	-$190.29M	-$0.45	N/A

vTv Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Summary

vTv Therapeutics beats Canopy Growth on 11 of the 17 factors compared between the two stocks.

Get vTv Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTVT vs. The Competition

Export

Metric	vTv Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$120.45M	$12.18B	$7.09B	$13.24B
Dividend Yield	N/A	2.63%	2.53%	15.88%
P/E Ratio	-28.84	797.15	274.61	26.05
Price / Sales	118.08	751.67	600.52	89.39
Price / Cash	N/A	81.79	77.38	51.25
Price / Book	1.87	10.47	10.92	6.31
Net Income	-$26.97M	$2.83B	$3.50B	$361.43M
7 Day Performance	1.19%	-1.65%	-2.11%	-1.67%
1 Month Performance	-8.47%	-5.77%	-6.34%	-3.94%
1 Year Performance	29.81%	-3.80%	8.81%	2.77%

vTv Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTVT vTv Therapeutics	2.3352 of 5 stars	$30.57 -4.0%	$55.83 +82.6%	+32.7%	$120.45M	$1.02M	N/A	26
TTRX Turn Therapeutics	1.9956 of 5 stars	$15.29 -0.3%	$9.00 -41.1%	N/A	$456.95M	N/A	N/A	2
RLMD Relmada Therapeutics	2.7747 of 5 stars	$4.24 +1.9%	$12.00 +183.0%	+69.4%	$443.75M	N/A	N/A	17
AVIR Atea Pharmaceuticals	1.9076 of 5 stars	$5.64 +3.9%	$7.00 +24.1%	+77.1%	$435.51M	N/A	N/A	55
SPRY ARS Pharmaceuticals	1.9959 of 5 stars	$4.48 +3.0%	$26.40 +489.3%	-59.2%	$432.60M	$84.28M	N/A	200	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTVT) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

vTv Therapeutics (VTVT) Competitors

VTVT vs. TTRX, RLMD, AVIR, SPRY, and CGC

How does vTv Therapeutics compare to Turn Therapeutics?

Summary

How does vTv Therapeutics compare to Relmada Therapeutics?

Summary

How does vTv Therapeutics compare to Atea Pharmaceuticals?

Summary

How does vTv Therapeutics compare to ARS Pharmaceuticals?

Summary

How does vTv Therapeutics compare to Canopy Growth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT vs. The Competition

vTv Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

vTv Therapeutics (VTVT) Competitors

VTVT vs. TTRX, RLMD, AVIR, SPRY, and CGC

How does vTv Therapeutics compare to Turn Therapeutics?

Which has higher valuation & earnings, TTRX or VTVT?

Do institutionals and insiders have more ownership in TTRX or VTVT?

Do analysts prefer TTRX or VTVT?

Is TTRX or VTVT more profitable?

Does the media refer more to TTRX or VTVT?

Summary

How does vTv Therapeutics compare to Relmada Therapeutics?

Do analysts rate RLMD or VTVT?

Does the media prefer RLMD or VTVT?

Which has higher earnings and valuation, RLMD or VTVT?

Is RLMD or VTVT more profitable?

Do institutionals & insiders hold more shares of RLMD or VTVT?

Which has more risk and volatility, RLMD or VTVT?

Summary

How does vTv Therapeutics compare to Atea Pharmaceuticals?

Do analysts prefer AVIR or VTVT?

Does the media prefer AVIR or VTVT?

Is AVIR or VTVT more profitable?

Do insiders and institutionals believe in AVIR or VTVT?

Which has higher valuation and earnings, AVIR or VTVT?

Which has more risk and volatility, AVIR or VTVT?

Summary

How does vTv Therapeutics compare to ARS Pharmaceuticals?

Which has more volatility & risk, VTVT or SPRY?

Which has preferable valuation and earnings, VTVT or SPRY?

Does the media refer more to VTVT or SPRY?

Do analysts prefer VTVT or SPRY?

Do insiders & institutionals believe in VTVT or SPRY?

Is VTVT or SPRY more profitable?

Summary

How does vTv Therapeutics compare to Canopy Growth?

Do institutionals & insiders have more ownership in VTVT or CGC?

Do analysts recommend VTVT or CGC?

Is VTVT or CGC more profitable?

Does the media favor VTVT or CGC?

Which has better valuation & earnings, VTVT or CGC?

Which has more volatility & risk, VTVT or CGC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT vs. The Competition

vTv Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools